MAPT and early-onset autosomal dominant Alzheimer disease: Our results indicate that tau-PET may serve as a robust biomarker for the identification of Aβ-positive patients with tau-positivity (A + T+).26 Since these individuals have a greater susceptibility to experiencing future cognitive decline, using this population for clinical trial designs would be beneficial for studying those at risk for Alzheimer’s disease.27 Some important derivations could be made based on our findings.